Clinical Extension Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) The primary objective of the study is to evaluate the long-term safety profile of dexpramipexole in subjects with ALS.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) Subjects Impacto de natalizumab frente a fingolimod en lesiones del tejido del sistema nervioso central y en la recuperación de sujetos con esclerosis múltiple recidivante-remitente activa The primary objective of the study is to assess the effect of natalizumab compared to fingolimod on the evolution of new on-treatment T1-gadolinium-enhancing (Gd+) lesions to persistent black holes (P...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Immunogenicity and Safety Study of Natalizumab (BG00002) administered to Participants with Relapsing Multiple Sclerosis The primary objective of this study is to evaluate the immunogenicity of natalizumab 300 mg SC administered to subjects with relapsing MS.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and Safety of BIIB074 in Participants with Trigeminal Neuralgia Placebem kontrolované, dvojitě zaslepené, randomizované, vyřazovací klinické hodnocení fáze 3 posuzující účinnost a bezpečnost přípravku BIIB074 u pacientů s neuralgií trigeminu The primary objective of the study is to evaluate the efficacy of BIIB074 in treating pain experienced by subjects with TN. The primary objective of the LTE phase of the study is to evaluate the lo...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Follow-Up Study to Look at Long-Term Responses in Subjects who previously took part in Study 215ON201 The primary objective of the study is to assess full-field visual evoked potential (FF-VEP) latency in subjects who were enrolled in Study 215ON201 at 2 years (+ up to 12 months) after the last study ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to Evaluate BIIB059 in CLE with or without SLE The primary objective of the study is to evaluate the efficacy of BIIB059 in reducing skin disease activity in participants with systemic lupus erythematosus (SLE) (Part A), and in participants with a...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) The primary objective of the study is to evaluate the effect of BG00012 on lymphocyte subset counts during the first year of treatment in subjects with RRMS.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to compare the safety and efficacy of BIIB033 to a placebo in patients with first episode of loss of vision due to acute inflammation in the optic nerve The primary objective of the study is to evaluate the efficacy of BIIB033 in subjects with their first episode of unilateral AON.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study of BG00012 on MRI lesions and Pharmacokinetics in children from 10 to less than 18 years old with a type of Multiple Sclerosis called 'Relapsing, Remitting Multiple Sclerosis' The primary objective of this study is to evaluate the effect of BG00012 on brain MRI lesions in paediatric subjects with RRMS

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study to assess the safety and tolerability of ISIS 396443 in participants with spinal muscular atrophy (SMA) The primary objective of Part 1 the study is to assess the safety and tolerability of ISIS 396443 in participants with SMA who are not eligible to participate in the clinical studies ISIS 396443-CS3B ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune